OBJECTIVES: Upon completion of this activity, the participant should be able to:
1.  Describe how p16 status and staging separate HPV-associated from HPV-negative disease in prognosis and treatment intensity.
2.  Discuss and compare transoral surgery with primary chemoradiation and identify the pathologic risk features that determine adjuvant therapy.
3.  Explain why de-escalation trials did or did not change practice, and discuss the patients who are poor candidates for reduced-intensity treatment.

FACULTY DISCLOSURE: Dr. Mopileola Tomi Adewumi has no relevant financial relationship(s) with companies whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.

PLANNER DISCLOSURE: The planners have no relevant financial relationship(s) with companies whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.

ACCREDITATION: The A. Webb Roberts Center for Continuing Medical Education of Baylor Scott & White Health is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

DESIGNATION:  The A. Webb Roberts Center for Continuing Medical Education of Baylor Scott & White Health designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit™.  Physicians should claim only the credit commensurate with the extent of their participation in the activity.

CE BROKER: For Texas physicians who have updated their EthosCE profile, credit claimed for this activity will be reported to CE Broker.

For information, please contact [email protected]

MEETING LINK:

Microsoft Teams meeting

Join: https://teams.microsoft.com/meet/239589443055?p=xx4bkzlvLQRZJXpQde

Meeting ID: 239 589 443 055

Passcode: 8yy9we6s